Lintitript

DB04867ExperimentalSmall molecule

Lintitript is a new, highly specific and potent CCK-A receptor antagonist.

Mechanism: Cholecystokinin (CCK) modulates feeding and dopamine-induced behavior in the central and peripheral nervous system. Lintitript antagonizes the effect of cholecystokinin by binding to the cholecystokinin type A (CCK-A) receptor. This action presumably alters feeding habits, however the exact mechanism of action is not known.
Curator reviewed
Primary indication: For the treatment of pancreatic cancer and appetite disorders.Curator reviewed
Formula / weight: C₂₀H₁₄ClN₃O₃S · 411.861 g/mol (avg)
Code names: SR 27897

Resolves to

Compound

Structure

InChIKeyILNRQFBVVQUOLP-UHFFFAOYSA-NSMILESOC(=O)CN1C(=CC2=CC=CC=C12)C(=O)NC1=NC(=CS1)C1=CC=CC=C1Cl

Targets

What you can answer from here — as of October 01, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Lintitript, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.